TONADO™ study shows further benefits in COPD
Data from the pivotal Phase III TONADO™ studies for tiotropium + olodaterol Respimat® fixed dose combination (FDC) were presented for the first time at the European Respiratory Society (ERS) International Congress 2014 in Munich.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Industry News Respiratory copd fixed dose combination Latest News phase iii trial tiotropium olodaterol Source Type: news
More News: Chronic Obstructive Pulmonary | Clinical Trials | Drugs & Pharmacology | Politics | Respiratory Medicine | Spiriva | Study | Tiotropium